Homeopathic Medicines in Third (Omicron) Wave of COVID-19: Prognostic Factor Research

Abstract

Background With the emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, such as the Omicron variant, during the third wave of the coronavirus disease 2019 (COVID-19) pandemic, there was a need to identify useful homeopathic medicines. This study aimed to identify such medicines and their indications using prognostic factor research (PFR).

Methods This was an open-label, multi-centred observational study conducted in January 2022, on confirmed COVID-19 cases. The data were collected from integrated COVID Care Centres in Delhi, India, where homeopathic medicines were prescribed along with conventional treatment. Only those cases that met a set of selection criteria were considered for analysis. The likelihood ratio (LR) was calculated for the frequently occurring symptoms of the frequently prescribed medicines. An LR of 1.3 or greater was considered meaningful.

Results Out of the 362 COVID-19 cases, 263 cases were selected for analysis after applying selection criteria. Common symptoms included fatigue, cough, sore throat, myalgia and headache. Twenty-one medicines were prescribed, of which nine medicines – Gelsemium sempervirens, Bryonia alba, Hepar sulphuris, Rhus toxicodendron, Pulsatilla nigricans, Arsenicum album, Belladonna, Nux vomica and Phosphorus – were frequently used. By calculating LRs, the study identified meaningful indications for these medicines.

Conclusion Homeopathic medicines have shown promising results in the third wave of COVID-19 as an adjunct therapy. The medicines that were used in the first and second waves were found useful in the third wave also, and their indications were analogous to those found in the earlier waves. Certain new indications of some medicines were elicited in this wave, which warrant further research. However, it is important not to restrict to these medicines only and to continue data collection on COVID-19 in future waves for the improvement of the COVID-19 mini-repertory.

Keywords

COVID-19 - third wave - homeopathy - prognostic factor research - likelihood ratio

• References

• 1 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733
• 2 Jean SS, Hsueh PR. Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther 2020; 18: 843-847
• 3 Rogosnitzky M, Berkowitz E, Jadad AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: the COVID-19 pandemic as a case in point. JMIR Public Health Surveill 2020; 6: e19199
• 4 Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020; 72: 1479-1508
• 5 To KLA, Fok YYY. Homeopathic clinical features of 18 patients in COVID-19 outbreaks in Hong Kong. Homeopathy 2020; 109: 146-162
• 6 Rossi EG. The experience of an Italian public homeopathy clinic during the COVID-19 epidemic, June–May 2020. Homeopathy 2020; 109: 167-168
• 7 Masiello DJ. The COVID-19 pandemic: a view from New York City. Homeopathy 2020; 109: 163-166
• 8 Manchanda RK, Miglani A, Gupta M. et al. Homeopathic medicines in COVID-19: prognostic factor research. Homeopathy 2021; 110: 160-167
• 9 Jethani B, Gupta M, Wadhwani P. et al. Clinical characteristics and medicine profiles of patients with COVID-19: a retrospective cohort study. Homeopathy 2021; 110: 86-93
• 10 Vaishampayan S, Mutreja K, Lambe S, Shah J, Shaikh G. Mercurius solubilis as Genus Epidemicus for the COVID-19 pandemic. Homeopathy 2020; 109: 271-272
• 11 Manchanda RK, Miglani A, Chakraborty M. et al. Impact of bias in data collection of COVID 19 cases. Homeopathy 2022; 111: 57-65
• 12 Rutten L, Miglani A, Gold P. et al. Generalizability of homeopathic prognostic factor research outcome in COVID-19 treatment: comparison of data. Homeopathy 2022; 111: 157-163
• 13 World Health Organization declares Indian coronavirus variant 'of concern'. Accessed May 23, 2023 at: https://www.business-standard.com/article/current-affairs/world-health-organization-declares-indian-coronavirus-variant-of-concern-121051100617_1.html
• 14 Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-19 in India. Lancet Respir Med 2021; 9: e93-e94
• 15 Sengupta P, Ganguli B, SenRoy S, Chatterjee A. An analysis of COVID-19 clusters in India: Two case studies on Nizamuddin and Dharavi. BMC Public Health 2021; 21: 631
• 16 Manchanda RK, Miglani A, Chakraborty M. et al. Homeopathic medicines in second wave of COVID-19: prognostic factor research. Homeopathy 2023; 112: 12-21
• 17 Miglani A, Manchanda RK, Kalsi A. et al. Test of a homeopathic algorithm for COVID-19: the importance of a broad perspective. Homeopathy 2023; 112: 22-29
• 18 Centers for Disease Control and Prevention. Omicron variant: what you need to know. Updated on February 6, 2023 . Accessed May 23, 2023 at: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html
• 19 World Health Organization. Update on Omicron. Updated on November 28, 2021 . Accessed May 23, 2023 at: https://www.who.int/news/item/28-11-2021-update-on-omicron
• 20 Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther 2022; 7: 141
• 21 The Times of India. COVID symptoms: four symptoms of Omicron that are different from Delta. Updated on December 27, 2021 . Accessed May 23, 2023 at: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/coronavirus-omicron-variant-symptoms-vs-delta-variant-four-symptoms-of-omicron-that-are-different-from-delta/photostory/88493946.cms
• 22 Mount I. There's one big difference between Omicron and Delta symptoms, a major new study finds. Here's how to tell them apart. Accessed May 23, 2023 at: https://fortune.com/2022/04/08/omicron-symptoms-covid-19-different-delta-lancet-study-uk/
• 23 AIIMS/ICMR-COVID-19 National Task Force / Joint Monitoring Group. Clinical Guidance for Management of Adult COVID-19 Patients; Revised on 05/01/2023. Ministry of Health & Family Welfare, Government of India. Accessed May 23, 2023 at: https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Clinical_Management_19032023.pdf
• 24 Indian Council of Medical Research. Advisory on Purposive Testing Strategy for COVID-19 in India (Version VII, dated 10th January, 2022). Accessed May 23, 2023 at: https://www.icmr.gov.in/pdf/covid/strategy/Advisory_COVID_Testing_10012022.pdf
• 25 Ho CS, Chee CY, Ho RC. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singap 2020; 49: 155-160
• 26 Miglani A. Effect of lockdown during COVID-19: an Indian perspective. Int J Sci Healthcare Res 2020; 5: 55-61
• 27 Reilly D, Mercer SW, Bikker AP, Harrison T. Outcome related to impact on daily living: preliminary validation of the ORIDL instrument. BMC Health Serv Res 2007; 7: 139
• 28 van Haselen RA. Homeopathic clinical case reports: development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline. Complement Ther Med 2016; 25: 78-85
• 29 Miglani A, Rutten L, Manchanda RK. Generalisability of prognostic factor research: further analysis of data from the IIPCOS2 study. Homeopathy 2017; 106: 155-159
• 30 Menni C, Valdes AM, Polidori L. et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022; 399: 1618-1624